<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00266747</url>
  </required_header>
  <id_info>
    <org_study_id>EFC5893</org_study_id>
    <nct_id>NCT00266747</nct_id>
  </id_info>
  <brief_title>An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder</brief_title>
  <acronym>AQUARIUS</acronym>
  <official_title>An Eight-Week,Dble-Blind,Placebo-Controlled, Multicenter Study With Paroxetine (20 mg q24) as Positive Control, Evaluating the Efficacy, Safety and Tolerability of a Fixed Dose of SR58611A (350 mg q12) in Outpatients With Generalized Anxiety Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of SR58611A in patients with&#xD;
      Generalized Anxiety Disorder. The primary objective is to evaluate the efficacy of a 700 mg&#xD;
      dose of SR58611A compared to placebo in patients with generalized anxiety disorder (GAD).The&#xD;
      secondary objectives are to evaluate the efficacy of SR58611A on disability and quality of&#xD;
      life in patients with GAD and to evaluate safety of SR58611A.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a multicenter, multicountry, randomized, parallel-group, double blind, placebo&#xD;
      and paroxetine-controlled study consisting of three segments (A, B, and C). Segment A is a&#xD;
      1-week, placebo, single-blind period and Segment B is an 8-week, double blind period. All&#xD;
      randomized patients must complete a post-study visit 1 week after intake of the last dose of&#xD;
      study medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome of the study is the change from baseline to Day 56 of treatment in the Hamilton Anxiety Rating Scale (HAM-A) total score.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The main secondary outcomes are the changes from baseline to Day 56 of treatment in the CGI Severity of Illness Score, percentage of patients with HAM-A treatment response and change from baseline in the HAM-A somatic and psychic anxiety factor scores.</measure>
  </secondary_outcome>
  <enrollment type="Actual">366</enrollment>
  <condition>Anxiety Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SR58611A</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Out-patients, 18 to 65 years of age.&#xD;
&#xD;
          -  Patients suffering from generalized anxiety disorder (GAD) as defined by Diagnostic&#xD;
             and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR)&#xD;
             criteria and confirmed by the Mini International Neuropsychiatric Interview (MINI)&#xD;
             plus GAD Module.&#xD;
&#xD;
          -  With a total score on the 14-item Hamilton Anxiety Rating Scale (HAM-A) ³ 20.&#xD;
&#xD;
          -  Having given voluntarily their written informed consent to participate in the study.&#xD;
&#xD;
          -  Able to comply with the protocol and follow written and verbal instructions.&#xD;
&#xD;
          -  For inclusion into Segment B of the study, patients must fulfill the following&#xD;
             criteria:&#xD;
&#xD;
          -  All Segment A inclusion criteria.&#xD;
&#xD;
          -  Completion of a minimum of 3 and a maximum of 9 days of treatment in Segment A.&#xD;
&#xD;
          -  Not &quot;placebo responders&quot; (i.e., improvement £ 20 % on HAM-A total score between V1 and&#xD;
             V2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of Major Depressive Disorder as defined by DSM-IV-TR within&#xD;
             6 months of study entry.&#xD;
&#xD;
          -  Patients with a Montgomery-Asberg Depression Rating Scale (MADRS) total score of 18 or&#xD;
             higher at screening or baseline visits.&#xD;
&#xD;
          -  Patients having a moderate to high current risk for suicide.&#xD;
&#xD;
          -  Patients with other current anxiety disorder assessed with the MINI: agoraphobia,&#xD;
             social phobia, panic disorder, obsessive-compulsive disorder, post-traumatic stress&#xD;
             disorder, acute stress disorder.&#xD;
&#xD;
          -  Patients with a lifetime history according to the MINI of: bipolar disorders,&#xD;
             psychotic disorders, antisocial personality disorder.&#xD;
&#xD;
          -  Patients with severe or unstable concomitant medical conditions according to the&#xD;
             Investigator's judgment.&#xD;
&#xD;
          -  Females who are pregnant or lactating.&#xD;
&#xD;
          -  Female patients of childbearing potential must use an effective method of birth&#xD;
             control during the entire study period.&#xD;
&#xD;
          -  Patients with positive test for any illicit drug included in the urine drug screen.&#xD;
&#xD;
          -  Participation in a clinical trial of an experimental therapy within 3 months prior to&#xD;
             screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bromma</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Mexico</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.sanofi-aventis.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>December 16, 2005</study_first_submitted>
  <study_first_submitted_qc>December 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2005</study_first_posted>
  <last_update_submitted>March 10, 2009</last_update_submitted>
  <last_update_submitted_qc>March 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Anxiety</keyword>
  <keyword>Anti-Anxiety Agents</keyword>
  <keyword>Controlled Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amibegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

